Gamida Cell - Cord Blood Transplant

Press Releases

Gamida Cell Reports StemEx® Phase II/III Study Safety and Efficacy Data
Apr. 11, 2013

Gamida Cell’s NiCord® Demonstrates Successful Engraftment in Patients with Hematological Malignancies in Phase I/II Study
Feb. 14, 2013

Gamida Cell’s StemEx® Achieves Primary Endpoint in Phase II/III Clinical Study
Feb. 4, 2013
Gamida Cell announced today that its flagship product, StemEx, reached its primary endpoint of improving overall survival in a Phase II/III study which compared the use of StemEx as part of a transplantation regimen to historical controls in the treatment of patients with hematological malignancies such as leukemia and lymphoma.

First Pediatric Sickle Cell Disease Patient Receives NiCord® Stem Cell Transplantation in Gamida Cell Pilot Study at Duke University
Nov. 12, 2012

Gamida Cell Completes Enrollment for Phase I/II Study of Second Pipeline Product Nicord® For Hematological Malignancies
Sep. 19, 2012

Gamida Cell Closes $10 Million E Financing Round Earmarked to Support the Global Commercialization of the Company’s Lead Product StemEx® for Leukemia and Lymphoma
May. 15, 2012

The Gamida Cell-Teva Joint Venture Concludes Enrollment for the Phase III Study of StemEx®, a Cord Blood Stem Cell Product, for Leukemia and Lymphoma
Feb. 13, 2012
The results of the StemEx study are expected during the second half of 2012

The Gamida Cell-Teva Joint Venture Receives Green Light From the Data Monitoring Committee to Continue the Phase III Study of StemEx®, a Cord Blood Stem Cell Product, for Leukemia and Lymphoma
Jul. 12, 2011

The Gamida Cell-TEVA Joint Venture Receives FDA Fast Track Designation for StemEx® for Leukemia and Lymphoma
Jun. 21, 2010

Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx®, a Cord Blood Stem Cell Product, for Leukemia and Lymphoma
Feb. 10, 2010

European Medicines Agency (EMA) Waives Requirement to Test StemEx® in Paediatric Patients 17 Years of Age and Under
Jan. 18, 2010

Gamida Cell Announces Feasibility Study with Weill Cornell Medical College
Dec. 2, 2009
Study is testing a new method to deliver gene correction cells to treat congenital conditions such as Cooley's Anemia

StemEx® Noted as a Reliable Investigational Product of an Expanded Population of Stem Cells at Umbilical Cord Blood Symposium in Israel
Nov. 2, 2009

Article Published in Expert Opinion on Biological Therapy Evaluates StemEx® (carlecortemcel-l) for Leukemia and Lymphoma
Sep. 30, 2009
The article, entitled Carlecortemcel-l, an ex vivo expanded umbilical cord blood cell graft for allogeneic transplantation, is now available online.

Children's Hospital in Colorado Enrolling for ExCell
Sep. 16, 2009
Children's Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemExֲ® for Leukemia and Lymphoma

UPCI Joins ExCell Research Study
Jun. 15, 2009
UPCI Joins ExCell Research Study Using Stem Cells for Leukemia and Lymphoma Patients

Five Cord Blood Transplant Centers in Catalonia and Valencia Join a Study to Test a New Technique to Treat Leukemia and Lymphoma
Jun. 3, 2009
The Gamida Cell-Teva Joint Venture announced today that five prestigious cord blood transplantations centers in Spain, three in Barcelona and two in Valencia, have joined the ExCell study.

Cinco centros de trasplante de sangre de cordón umbilical se unen a un estudio
Jun. 3, 2009
Cinco centros catalanes y valencianos de trasplante de sangre de cordón umbilical se unen a un estudio con una nueva técnica candidata a terapia contra la leucemia y el linfoma

President of Israel Shimon Peres Tours Gamida Cell in Jerusalem
May. 20, 2009
Gamida Cell is a world leader in adult stem cell technologies and products.

The Western Pennsylvania Hospital Joins Prominent Group of Cancer Centers
Mar. 19, 2009
The Western Pennsylvania Hospital Joins Prominent Group of Cancer Centers Exploring New Therapy for Leukemia and Lymphoma Patients. ExCell study assessing the safety and efficacy of StemEx® as an alternative to bone marrow transplants

StemEx®, a Gamida Cell-TEVA Joint Venture Cell Therapy Product, Receives Orphan Medicinal Product Designation in the European Union
Mar. 11, 2009
StemEx is now being researched in a Phase III study called ExCell assessing the safety and efficacy of StemEx as an alternative to bone marrow transplants for leukemia and lymphoma patients

Choc Children’s Joins Excell Pivotal Study For Leukemia And Lymphoma Patients As Only Pediatric Site On West Coast
Feb. 19, 2009
Trial studying StemEx® as a bone marrow transplant alternative.

Children’s Memorial Hospital Joins Excell Pivotal Study
Jan. 13, 2009

Press Releases Archive

Recent
2008
2007
2006
2005
2004
2003

To learn more about our products and clinical trials, please fill in:
Name: 
Email: 
Country: 
* Message:
* Please type in the verification code as appears on the image: